Pacira BioSciences, Inc.
PCRX
$24.45
$1.054.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 702.77M | 700.97M | 694.96M | 690.31M | 681.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 702.77M | 700.97M | 694.96M | 690.31M | 681.75M |
| Cost of Revenue | 204.49M | 217.16M | 220.53M | 223.14M | 226.88M |
| Gross Profit | 498.29M | 483.81M | 474.43M | 467.17M | 454.87M |
| SG&A Expenses | 308.85M | 294.10M | 280.29M | 273.90M | 270.62M |
| Depreciation & Amortization | 57.29M | 57.29M | 57.29M | 57.29M | 57.29M |
| Other Operating Expenses | 351.00K | -- | -- | -- | -- |
| Total Operating Expenses | 612.49M | 603.39M | 592.95M | 589.18M | 588.33M |
| Operating Income | 90.29M | 97.57M | 102.01M | 101.13M | 93.42M |
| Income Before Tax | -68.04M | -63.11M | -54.91M | 100.55M | 101.82M |
| Income Tax Expenses | 35.69M | 36.45M | 35.82M | 36.95M | 31.35M |
| Earnings from Continuing Operations | -103.73 | -99.56 | -90.73 | 63.59 | 70.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.73M | -99.56M | -90.73M | 63.59M | 70.47M |
| EBIT | 90.29M | 97.57M | 102.01M | 101.13M | 93.42M |
| EBITDA | 171.81M | 176.36M | 178.03M | 175.34M | 167.82M |
| EPS Basic | -2.25 | -2.16 | -1.97 | 1.37 | 1.52 |
| Normalized Basic EPS | 1.29 | 1.36 | 1.41 | 1.37 | 1.23 |
| EPS Diluted | -2.29 | -2.20 | -1.99 | 1.34 | 1.47 |
| Normalized Diluted EPS | 1.23 | 1.27 | 1.30 | 1.23 | 1.10 |
| Average Basic Shares Outstanding | 184.75M | 184.98M | 185.24M | 185.53M | 185.44M |
| Average Diluted Shares Outstanding | 192.24M | 197.90M | 200.93M | 206.86M | 208.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |